News

The objective response rate (ORR) was 32% with adagrasib versus 9% with docetaxel (OR 4.68, 95% CI 2.56-8.56, P <0.0001), ...
Doting father-of-two John O'Neill from Althorne, Essex, had a one in 50,000 reaction to the AstraZeneca jab in May 2021 that ...
Latest move to cut funding for vaccines is not down to US health secretary. It is part of Trump’s wider war on science.
These are three of the most popular UK shares being bought by British investors, but are they actually good investments in 2025? The post 1 no-brainer UK share to consider buying with £3,000? appeared ...
None of the fatalities, however, are proven to have been caused by SSRIs, a category of drugs including sertraline and ...
With a 5.98% market share, India is the fourth-largest pharmaceutical supplier to the U.S., behind Ireland, Switzerland, and ...
Tempus AI Inc (TEM) reports an 89.6% revenue surge and strategic financial improvements, despite ongoing challenges in reimbursement and profitability.
Q2 2025 Earnings Call Transcript August 8, 2025 Operator: Welcome to the Lisata Therapeutics Second Quarter 2025 Financial ...
IonQ’s IONQ second quarter of 2025 marked a major turning point for the quantum computing giant in several ways. On the computing side, IonQ is accelerating toward 800 logical qubits by 2027 and ...
Donald Trump’s plan to force down drug prices in the United States by demanding pharmaceutical companies raise prices in ...
In results from a Phase Ib study, Hernexeos showed a 75 percent response rate and more than half of patients responded for at least six months.
"In one year, one and a half years maximum, it's going to go to 150% and then it's going to go to 250% because we want ...